CareDx said it will prioritise a cell therapy surveillance testing pipeline in 2026 after reporting solid quarterly revenue growth. The company published validation data from the ACROBAT observational trial showing its AlloHeme cell‑free DNA assay can predict relapse in allogeneic hematopoietic cell transplant patients with AML and myeloid dysplasias. Management flagged AlloHeme as a pillar of its 'Transplant Plus' strategy to expand beyond solid‑organ transplant diagnostics into hematology and oncology. CareDx also warned that a draft Medicare local coverage determination could cut revenue by an estimated $7.5–$15 million if finalized, underscoring payer/regulatory risk to surveillance testing growth.